SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN), a leading developer, manufacturer and marketer of life science tools and integrated systems for the analysis of genetic variation and function, today recommended that its stockholders take no action at this time in response to Roche’s announcement that it is now offering to acquire Illumina for $51.00 per share in cash.
